Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 10,10 € (+282,58 %). La mediana es de 10,10 € (+282,58 %).
| Comprar |
12 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
X4 Pharmaceuticals reduces sample size of 4WARD phase III study and streamlines market‑launch plan
X4 Pharmaceuticals lowered the recruitment target for the 4WARD phase III study to 126 patients after consulting with the FDA and says this retains 88% power for the infection‑rate endpoint and 93% for the ANC endpoint. Recruitment is now in the triple digits and accelerated after the switch to Parexel, and the company expects study completion and top‑line data in early 2026. X4 plans a US commercial model with 50–60 field sales representatives, is preparing a G‑CSF titration study to boost physician uptake, and considers funding through 2029 sufficient for the next steps. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 7,72 M | 360,94 % |
| Beneficio bruto | 6,3 M | 401,99 % |
| Beneficio neto | -14,16 M | 35,18 % |
| EBITDA | -11,19 M | 42,91 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 248,41 M € |
Número de acciones | 94,32 M |
Máximo/mínimo de 52 semanas | 4,24 € - 2,46 € |
| Dividendos | No |
Beta | 0,35 |
Ratio P/E | -2,50 |
Ratio PEG | -0,01 |
Ratio P/B | 2,44 |
Ratio P/S | 17,86 |
Perfil de la empresa
| Nombre | X4 PHARMACEUTICALS INC |
| CEO | Adam R. Craig |
| Empleados | 45 |
